Rosetta polishes off Wishbone, announces new leadership

Share this article:
Rosetta polishes off Wishbone, announces new leadership
Rosetta polishes off Wishbone, announces new leadership
Wishbone founder Steve Michaelson and chief strategy officer Judy Capano have retired and the shop has been absorbed into Rosetta, months after its acquisition by Publicis.

Wishbone Rosetta operated as a standalone unit following the sale of Wishbone to Rosetta at the end of 2009, but the shop has now dropped the Wishbone name and been incorporated wholly into Rosetta, which Publicis bought in May.

The Wishbone business will now operate as part of a Rosetta healthcare vertical to be led by a team of four, including Wishbone creative lead Steve Hamburg, who directs the firm's professional and brand-building capabilities, and from the Rosetta side: Jamie Peck, who leads account management and business development; Shannon Hartley, who leads the Rosetta consulting practice and project management; and Brian Lucotch, who heads technology. The team reports to Hari Mahadevan, PhD, executive officer, consulting services and healthcare at Rosetta.

Capano will stay on as a consultant to the firm, training employees and running client workshops. Michaelson will continue his work with the Make a Wish Foundation and as a board member for several industry organizations.

Healthcare is the biggest driver of Rosetta's $240 million business, having brought in $68 million last year and with healthcare-related revenues forecast to be in that range for this year. Publicis acquired the network in a $575 million, all-cash deal that gave Rosetta global reach and Publicis another leading digital healthcare company to join a stable that includes Razorfish and Digitas. Publicis has left Rosetta a standalone network while consolidating back end services for Digitas and Razorfish in its VivaKi network.

Rosetta has nine offices in the US and Canada, with New York, Princeton and Cleveland offices, in particular, handling healthcare accounts. Clients include Otsuka, Takeda, Bristol-Myers Squibb, Forest and Allergan Europe.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.